NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model

被引：2
|
作者：
Sola, Caroline
Arnoux, Thomas
Chanuc, Fabien
Fuseri, Nicolas
Rossi, Benjamin
Gauthier, Laurent
Leget, Corinne
Bonnafous, Cecile
Wagtmann, Nicolai
Morel, Yannis
Andre, Pascale
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2342
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2342
引用
收藏
页数：4
相关论文
共 50 条
  • [1] PD-L1 blockade enhances anti-tumor efficacy of NK cells
    Oyer, Jeremiah L.
    Gitto, Sarah B.
    Altomare, Deborah A.
    Copik, Alicja J.
    [J]. ONCOIMMUNOLOGY, 2018, 7 (11):
  • [2] Indoximod Strongly Enhances Effects of Combined Hrt and PD1/PD-L1 Checkpoint Blockade
    Watanabe, T.
    Niedermann, G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E652 - E652
  • [3] IDO inhibition strongly enhances effects of combined hRT and PD1/PD-L1 checkpoint blockade
    Watanabe, T.
    Niedermann, G.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S72 - S73
  • [4] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
    Duruisseaux, Michael
    Rouquette, Isabelle
    Adam, Julien
    Cortot, Alexis
    Cazes, Aurelie
    Gibault, Laure
    Damotte, Diane
    Lantuejoul, Sylvie
    [J]. ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
  • [5] PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
    A. Filippone
    M. Lanza
    D. Mannino
    G. Raciti
    C. Colarossi
    D. Sciacca
    S. Cuzzocrea
    I. Paterniti
    [J]. Cancer Immunology, Immunotherapy, 2022, 71 : 2067 - 2075
  • [6] PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression
    Filippone, A.
    Lanza, M.
    Mannino, D.
    Raciti, G.
    Colarossi, C.
    Sciacca, D.
    Cuzzocrea, S.
    Paterniti, I
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (09) : 2067 - 2075
  • [7] Efficacy of ANTI-GD2 Antibody CH14.18/CHO and PD1/PD-L1 Checkpoint Blockade in Neuroblastoma
    Lode, H.
    Zumpe, M.
    Juttner, M.
    Troschke-Meurer, S.
    Loibner, H.
    Siebert, N.
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 : S42 - S42
  • [8] Preclinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors.
    Thi, Emily P.
    Cole, Andrew G.
    Heffernan, Gavin
    Iott, Christina L.
    Ozturk, Seyma
    Ganchua, Sharie C.
    Nguyen, Dan
    Graves, Ingrid
    Quintero, Jorge G.
    Stever, Kim
    Fan, Kristi
    Ahuja, Vijay
    Kultgen, Steven G.
    Shubina, Maria
    Liu, Boya
    Tang, Sunny
    Harasym, Troy
    Lam, Angela M.
    Sofia, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Mahoney, Kathleen M.
    Freeman, Gordon J.
    McDermott, David F.
    [J]. CLINICAL THERAPEUTICS, 2015, 37 (04) : 764 - 782
  • [10] Host immunogenetics and hyperprogression under PD1/PD-L1 checkpoint inhibitors
    Refae, Sadal
    Ebran, Nathalie
    Gal, Jocelyn
    Otto, Josiane
    Giacchero, Damien
    Borchiellini, Delphine
    Guigay, Joel
    Peyrade, Frederique
    Milano, Gerard
    Saada, Esma
    [J]. CANCER RESEARCH, 2018, 78 (13)
12345